Maxeon Solar Technologies 株価情報 (NASDAQ: MAXN)

Maxeon Solar Technologies (NASDAQ:MAXN) 株価情報

Maxeon Solar Technologies

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.

Maxeon Solar Technologies, Ltd. - Ordinary Shares

Maxeon Solar Technologies Ltd

Mizuho analyst David Belinger initiates coverage on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral rating and announces Price Target of $975.

News

Price Target

Initiation

Analyst Ratings

COST

Mizuho Initiates Coverage On Costco Wholesale with Neutral Rating, Announces Price Target of $975

VERV

Verve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9

Biotech

General

CATX

Perspective Therapeutics Doses First Patient With [212Pb]VMT01 Monotherapy At 1.5 mCi In Phase 1/2a Study Of MC1R-Positive Metastatic Melanoma

Mizuho analyst David Belinger initiates coverage on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral rating and announces Price Target of $92.

Mizuho Initiates Coverage On Target with Neutral Rating, Announces Price Target of $92

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Morgan Stanley analyst Kristine Liwag downgrades Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Overweight to Equal-Weight and lowers the price target from $10 to $7.

Downgrades

JOBY

Morgan Stanley Downgrades Joby Aviation to Equal-Weight, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $7.5 price target.

Reiteration

UNCY

HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7.5 Price Target

Earnings

JPMorgan Chase CEO Jamie Dimon: "The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility."

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.96 billion which beat the analyst consensus estimate of $1.95 billion by 0.45 percent. This is a 3.38 percent increase over sales of $1.90 billion the same period last year.

Earnings Beats

FAST

Fastenal Q1 2025 GAAP EPS $0.52, Inline, Sales $1.96B Beat $1.95B Estimate

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) with a Outperform and lowers the price target from $50 to $47.

BSVN

Keefe, Bruyette & Woods Maintains Outperform on Bank7, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and maintains $19 price target.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $5.07 per share which beat the analyst consensus estimate of $4.62 by 9.74 percent. This is a 14.19 percent increase over earnings of $4.44 per share from the same period last year. The company reported quarterly sales of $46.014 billion which beat the analyst consensus estimate of $44.111 billion by 4.31 percent. This is a 8.15 percent increase over sales of $42.548 billion the same period last year.

JPMorgan Chase Q1 2025 GAAP EPS $5.07 Beats $4.62 Estimate, Sales $46.014B Beat $44.111B Estimate

Wells Fargo Q1 net Interest Income Decreased 6%, Driven By The Impact Of Lower Interest Rates On Floating Rate Assets, Deposit Mix And Pricing Changes, Lower Loan Balances, And One Fewer Day In The Quarter, Partially Offset By Lower Market Funding

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

HC Wainwright &amp; Co. analyst Yi Chen reiterates VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $2.5 price target.

VNRX

HC Wainwright & Co. Reiterates Buy on VolitionRX, Maintains $2.5 Price Target

Earnings Misses

Wells Fargo Q1 2025 GAAP EPS $1.39 Beats $1.22 Estimate, Sales $20.149B Miss $20.748B Estimate

Goldman Sachs analyst Noah Poponak downgrades Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) from Buy to Neutral and lowers the price target from $6 to $3.5.

Goldman Sachs Downgrades Planet Labs to Neutral, Lowers Price Target to $3.5

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $4 price target.

HRTX

Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $720 price target.

ARGX

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target

Commodities

Stock Split

Press Releases

Maxeon Receives Nasdaq Notification and is Proceeding with Approved Reverse Stock Split

Pomerantz Law Firm Announces the Filing of a Class Action Against Maxeon Solar Technologies, Ltd. - MAXN

Maxeon Announces CEO Leadership Transition

Maxeon Provides Update on CBP Detention of its Solar Panels

Maxeon Announces Restructuring of Business Portfolio

Maxeon Solar Technologies Announces Third Quarter 2024 Financial Results

Maxeon and Tongwei Solar Announce Settlement Agreement Resolving Patent Infringement Lawsuit

Maxeon Provides Strategic Business Update

MAXN

Ascent Solar Technologies, Inc - Common Stock

Ascent Solar Technologies

Blaize Holdings

Datavault AI

GCT Semiconductor Holding, Inc. Common Stock

GCT Semiconductor Hldgs

GSI Technology

Intchains Group Limited - American Depositary Shares

Intchains Gr

Kopin

SemiLEDs

Mobix Labs

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

Nano Labs

Peraso

Pixelworks

QuickLogic

SmartKem

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Maxeon Solar Technologies

ニュース

パートナーシップ

ベンジンガ・グローバル